Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Fate Therapeutics (FATE) over the last 13 years, with Q3 2025 value amounting to 0.53%.

  • Fate Therapeutics' Return on Capital Employed fell 1200.0% to 0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53%, marking a year-over-year decrease of 1200.0%. This contributed to the annual value of 0.48% for FY2024, which is 1500.0% down from last year.
  • Fate Therapeutics' Return on Capital Employed amounted to 0.53% in Q3 2025, which was down 1200.0% from 0.54% recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' Return on Capital Employed registered a high of 0.17% during Q2 2021, and its lowest value of 0.54% during Q2 2025.
  • For the 5-year period, Fate Therapeutics' Return on Capital Employed averaged around 0.39%, with its median value being 0.41% (2024).
  • In the last 5 years, Fate Therapeutics' Return on Capital Employed skyrocketed by 2100bps in 2021 and then tumbled by -2700bps in 2022.
  • Quarter analysis of 5 years shows Fate Therapeutics' Return on Capital Employed stood at 0.25% in 2021, then crashed by -102bps to 0.5% in 2022, then increased by 22bps to 0.39% in 2023, then fell by -25bps to 0.49% in 2024, then dropped by -8bps to 0.53% in 2025.
  • Its last three reported values are 0.53% in Q3 2025, 0.54% for Q2 2025, and 0.51% during Q1 2025.